ATE516045T1 - Identifikation von vaccinia-virus-dominanten t- zell-epitopen - Google Patents
Identifikation von vaccinia-virus-dominanten t- zell-epitopenInfo
- Publication number
- ATE516045T1 ATE516045T1 AT04705315T AT04705315T ATE516045T1 AT E516045 T1 ATE516045 T1 AT E516045T1 AT 04705315 T AT04705315 T AT 04705315T AT 04705315 T AT04705315 T AT 04705315T AT E516045 T1 ATE516045 T1 AT E516045T1
- Authority
- AT
- Austria
- Prior art keywords
- vaccinia virus
- vaccinia
- identification
- cell epitopes
- dominant
- Prior art date
Links
- 206010046865 Vaccinia virus infection Diseases 0.000 title abstract 3
- 208000007089 vaccinia Diseases 0.000 title abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 241000700618 Vaccinia virus Species 0.000 abstract 3
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108700028369 Alleles Proteins 0.000 abstract 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 abstract 1
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 241000700647 Variola virus Species 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44284603P | 2003-01-24 | 2003-01-24 | |
| PCT/US2004/002141 WO2004067032A2 (en) | 2003-01-24 | 2004-01-26 | Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE516045T1 true ATE516045T1 (de) | 2011-07-15 |
Family
ID=32825265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04705315T ATE516045T1 (de) | 2003-01-24 | 2004-01-26 | Identifikation von vaccinia-virus-dominanten t- zell-epitopen |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US7217526B2 (de) |
| EP (1) | EP1624890B1 (de) |
| AT (1) | ATE516045T1 (de) |
| WO (1) | WO2004067032A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8067535B2 (en) * | 2003-01-24 | 2011-11-29 | The University Of Massachusetts | Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes |
| WO2004067032A2 (en) | 2003-01-24 | 2004-08-12 | University Of Massachusetts Medical Center | Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes |
| ITRM20030386A1 (it) * | 2003-08-05 | 2005-02-06 | Istituto Naz Per Le Malattie Infettive Lazz | Metodo e test diagnostici basati sull'analisi citofluorimetrica dei linfociti t antigene-specifici. |
| US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| US7807180B2 (en) | 2007-08-21 | 2010-10-05 | University Of Massachusetts | Poxvirus methods and compositions |
| WO2010039224A2 (en) | 2008-09-30 | 2010-04-08 | University Of Massachusetts Medical School | Respiratory syncytial virus (rsv) sequences for protein expression and vaccines |
| WO2012145509A2 (en) | 2011-04-19 | 2012-10-26 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors, and viruses |
| WO2015143558A1 (en) | 2014-03-27 | 2015-10-01 | British Columbia Cancer Agency Branch | T-cell epitope identification |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5766601A (en) | 1990-08-08 | 1998-06-16 | University Of Massachusetts Medical Center | Cross-reactive influenza a immunization |
| US5480799A (en) * | 1993-12-10 | 1996-01-02 | The University Of North Carolina At Chapel Hill | Sperm antigen corresponding to a sperm zona binding protein autoantigenic epitope |
| AUPM446594A0 (en) | 1994-03-16 | 1994-04-14 | Csl Limited | Cytotoxic t-cell epitopes identified within epstein-barr virus |
| WO1996003144A1 (en) | 1994-07-27 | 1996-02-08 | The Council Of The Queensland Institute Of Medical Research | Polyepitope vaccines |
| AUPO007396A0 (en) | 1996-05-24 | 1996-06-20 | Csl Limited | Ebv ctl epitopes |
| US5916872A (en) * | 1996-07-24 | 1999-06-29 | Intrabiotics Pharmaceuticals, Inc. | Cyclic peptides having broad spectrum antimicrobial activity |
| AUPO784197A0 (en) | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| IT1302026B1 (it) | 1997-08-22 | 2000-07-20 | Hoffmann La Roche | Materiali immunologici e metodi per la rivelazione di diidropirimidinadeidrogenasi. |
| US6962790B1 (en) | 1998-09-23 | 2005-11-08 | University Of Massachusetts Medical Center | Predictive assay for immune response |
| AU1598500A (en) | 1998-10-26 | 2000-05-15 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2 |
| US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| DE10108626A1 (de) | 2001-02-22 | 2002-09-05 | Sahin Ugur | Verfahren zur Identifizierung biologisch aktiver Strukturen mikrobieller Erreger |
| US7645456B2 (en) | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| WO2004024756A2 (en) * | 2002-09-12 | 2004-03-25 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Orthopoxvirus antigens and use thereof |
| DE10242318A1 (de) | 2002-09-12 | 2004-03-18 | GSF - Forschungszentrum für Umwelt und Gesundheit GmbH | Orthopoxvirusantigene und deren Verwendung |
| WO2004067032A2 (en) | 2003-01-24 | 2004-08-12 | University Of Massachusetts Medical Center | Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes |
-
2004
- 2004-01-26 WO PCT/US2004/002141 patent/WO2004067032A2/en active Application Filing
- 2004-01-26 US US10/764,985 patent/US7217526B2/en active Active
- 2004-01-26 AT AT04705315T patent/ATE516045T1/de not_active IP Right Cessation
- 2004-01-26 EP EP04705315A patent/EP1624890B1/de not_active Expired - Lifetime
-
2007
- 2007-03-30 US US11/731,784 patent/US7803566B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004067032A3 (en) | 2004-11-25 |
| US20050129703A1 (en) | 2005-06-16 |
| EP1624890B1 (de) | 2011-07-13 |
| WO2004067032A2 (en) | 2004-08-12 |
| US20070298046A1 (en) | 2007-12-27 |
| US7803566B2 (en) | 2010-09-28 |
| EP1624890A2 (de) | 2006-02-15 |
| US7217526B2 (en) | 2007-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hanke | Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines | |
| Germain | Vaccines and the future of human immunology | |
| Snyder et al. | Immunogenic peptide discovery in cancer genomes | |
| ATE267211T1 (de) | Impfstoff gegen hpv | |
| DE69936784D1 (de) | Behandlung von gebärmutterhalskrebs | |
| HUP0301180A2 (hu) | Imidazokinolinaminok adjuvánsként való használata DNS vakcinálásban | |
| PT1212358E (pt) | Genes sinteticos de papilomavirus humano | |
| ATE489969T1 (de) | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung | |
| DE60142615D1 (de) | Epitop-synchronisierung in antigen präsentierenden zellen | |
| HUP9901112A2 (hu) | Szintetikus HIV-gének | |
| CY1110585T1 (el) | ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ | |
| BRPI0518091A2 (pt) | mycobacterium, mÉtodo para permitir com que uma mycobacterium escape a partir de endossomos e preparaÇço para uma vacina | |
| BRPI0607605A2 (pt) | moléculas imunogênicas | |
| BRPI0409789A (pt) | vacina de tuberculose com eficácia aperfeiçoada | |
| ATE516045T1 (de) | Identifikation von vaccinia-virus-dominanten t- zell-epitopen | |
| DK1425404T3 (da) | Vaccinia-MVA-E3L-mutanter og anvendelse deraf | |
| WO2006023598A3 (en) | Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer | |
| Kroemer et al. | Can the exome and the immunome converge on the design of efficient cancer vaccines? | |
| DK0909323T3 (da) | Helicobacter pylori-bakterioferritin | |
| EA200701440A1 (ru) | Композиции для иммунизации против микобактерий | |
| WO2004044155A8 (en) | MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE | |
| ATE372350T1 (de) | Methode zur produktion oder verstärkung einer t- zell antwort gegen eine zielzelle durch verwendung eines komplexes aus einem hla klasse i moleküls und einer vorrichtung zum anheften | |
| DE60117053D1 (de) | Herstellung rekombinanter künstlicher hefe-chromosome, welche das genom des humanen cytomegalovirus enthalten | |
| Hoque et al. | Scrutinizing surface glycoproteins and poxin-schlafen protein to design a heterologous recombinant vaccine against monkeypox virus | |
| ATE283065T1 (de) | Mehrzweckvakzine gegen umhüllte viren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |